Search Results - "BRAKEMEIER, Susanne"

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial by Bissler, John J, Prof, Kingswood, J Christopher, FRCP, Radzikowska, Elżbieta, MD, Zonnenberg, Bernard A, MD, Frost, Michael, MD, Belousova, Elena, Prof, Sauter, Matthias, MD, Nonomura, Norio, Prof, Brakemeier, Susanne, MD, de Vries, Petrus J, Prof, Whittemore, Vicky H, PhD, Chen, David, PhD, Sahmoud, Tarek, MD, Shah, Gaurav, MD, Lincy, Jeremie, MS, Lebwohl, David, MD, Budde, Klemens, Prof

“…Summary Background Angiomyolipomas are slow-growing tumours associated with constitutive activation of mammalian target of rapamycin (mTOR), and are common in…”
Get full text

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study by Bissler, John J, Kingswood, J Chris, Radzikowska, Elzbieta, Zonnenberg, Bernard A, Belousova, Elena, Frost, Michael D, Sauter, Matthias, Brakemeier, Susanne, de Vries, Petrus J, Berkowitz, Noah, Voi, Maurizio, Peyrard, Severine, Budde, Klemens

“…We examined the long-term effects of everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis complex or sporadic…”
Get full text

The need for minimization strategies: current problems of immunosuppression by Bamoulid, Jamal, Staeck, Oliver, Halleck, Fabian, Khadzhynov, Dmytri, Brakemeier, Susanne, Dürr, Michael, Budde, Klemens

“…New immunosuppressants and the better use of immunosuppressant combination therapy have led to significant improvements in renal allograft outcomes over the…”
Get more information

Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects by Bamoulid, Jamal, Staeck, Oliver, Crépin, Thomas, Halleck, Fabian, Saas, Philippe, Brakemeier, Susanne, Ducloux, Didier, Budde, Klemens

“…Antithymocyte globulins (ATGs) are part of the immunosuppression arsenal currently used by clinicians to prevent or treat acute rejection in solid organ…”
Get full text

Obesity, Fat Tissue Parameters, and Arterial Stiffness in Renal Transplant Recipients by Heleniak, Zbigniew, Illersperger, Sarah, Brakemeier, Susanne, Dębska-Ślizień, Alicja, Budde, Klemens, Halleck, Fabian

“…Arterial stiffness and altered body composition (increased body fat mass [BFM] and decreased lean body mass) are acknowledged risk factors for adverse outcomes…”
Get full text

Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC) by Brakemeier, Susanne, Vogt, Lars, Adams, Lisa, Zukunft, Bianca, Diederichs, Gerd, Hamm, Bernd, Budde, Klemens, Makowski, Marcus R

“…Tuberous sclerosis complex (TSC)-associated renal angiomyolipoma (AML) have a high lifetime risk of acute bleeding. MTOR-inhibitors are a promising novel…”
Get full text

Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR) by Brakemeier, Susanne, Arns, Wolfgang, Lehner, Frank, Witzke, Oliver, Vonend, Oliver, Sommerer, Claudia, Mühlfeld, Anja, Rath, Thomas, Schuhmann, Robert, Zukunft, Bianca, Kroeger, Irena, Porstner, Martina, Budde, Klemens

“…Early conversion to everolimus was assessed in kidney transplant recipients participating in the Eurotransplant Senior Program (ESP), a population in whom data…”
Get full text

Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept by Choi, Mira, Bachmann, Friederike, Wu, Kaiyin, Lachmann, Nils, Schmidt, Danilo, Brakemeier, Susanne, Duerr, Michael, Kahl, Andreas, Eckardt, Kai-Uwe, Budde, Klemens, Nickel, Peter

“…In de novo kidney transplant recipients (KTR) treatment with belatacept has been established as a comparable option as maintenance immunosuppression,…”
Get full text

Differential impact of the CYP3A51 and CYP3A53 alleles on pre-dose concentrations of two tacrolimus formulations by Wehland, Markus, Bauer, Steffen, Brakemeier, Susanne, Burgwinkel, Philip, Glander, Petra, Kreutz, Reinhold, Lorkowski, Christine, Slowinski, Torsten, Neumayer, Hans H, Budde, Klemens

“…OBJECTIVESWe investigated the pharmacokinetic and pharmacogenetic implications of conversion from a twice-daily (P-Tac) to a once-daily (A-Tac) tacrolimus…”
Get full text

Selective Blockade of the Intermediate-Conductance Ca2+-Activated K+ Channel Suppresses Proliferation of Microvascular and Macrovascular Endothelial Cells and Angiogenesis In Vivo by Grgic, Ivica, Eichler, Ines, Heinau, Philipp, Si, Han, Brakemeier, Susanne, Hoyer, Joachim, Köhler, Ralf

“…OBJECTIVE—Ca-activated K (KCa) channels have been proposed to promote mitogenesis in several cell types. Here, we tested whether the intermediate-conductance…”
Get full text

Advances in pharmacotherapy to treat kidney transplant rejection by Bamoulid, Jamal, Staeck, Oliver, Halleck, Fabian, Dürr, Michael, Paliege, Alexander, Lachmann, Nils, Brakemeier, Susanne, Liefeldt, Lutz, Budde, Klemens

“…Current immunosuppressive combination therapy provides excellent prevention of T-cell-mediated rejection following renal transplantation; however,…”
Get more information

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients by Duerr, Michael, Schrezenmeier, Eva V, Lehner, Lukas J, Bergfeld, Léon, Glander, Petra, Marticorena Garcia, Stephan R, Althoff, Christian E, Sack, Ingolf, Brakemeier, Susanne, Eckardt, Kai-Uwe, Budde, Klemens, Halleck, Fabian

“…Only a few prospective trials exist regarding the use of novel direct-acting antiviral agents (DAAs) in kidney transplant recipients (KTR) with chronic…”
Get full text

Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis by KÖHLER, Ralf, WULFF, Heike, REAL, Robert, BORNER, Klaus, BRAKEMEIER, Susanne, ORZECHOWSKI, Hans-Dieter, REUSCH, Hans-Peter, PAUL, Martin, CHANDY, K. George, HOYER, Joachim, EICHLER, Ines, KNEIFEL, Marlene, NEUMANN, Daniel, KNORR, Andrea, GRGIC, Ivica, KÄMPFE, Doris, SI, Han, WIBAWA, Judith

“…Angioplasty stimulates proliferation and migration of vascular smooth muscle cells (VSMC), leading to neointimal thickening and vascular restenosis. In a rat…”
Get full text

Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation by Brakemeier, Susanne, Pfau, Anja, Zukunft, Bianca, Budde, Klemens, Nickel, Peter

“…Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection diagnosed in immunocompromized patients. After solid organ transplantation, early…”
Get full text

NT-PRO BNP, VISCERAL FAT AREA, CELL MEMBRANE INTEGRITY AND ARTERIAL STIFFNESS IN RENAL TRANSPLANT RECIPIENTS by Heleniak, Zbigniew, Illersberger, Sarah, Brakemeier, Susanne, Debska-Slizien, Alicja, Budde, Klemens, Halleck, Fabian

Get full text

Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial by Bissler, John J, Kingswood, John Christopher, Radzikowska, Elżbieta, Zonnenberg, Bernard A, Frost, Michael, Belousova, Elena, Sauter, Matthias, Nonomura, Norio, Brakemeier, Susanne, de Vries, Petrus J, Berkowitz, Noah, Miao, Sara, Segal, Scott, Peyrard, Severine, Budde, Klemens

“…Mammalian target of rapamycin (mTOR) inhibitors are recommended as first-line treatment of renal angiomyolipoma associated with tuberous sclerosis complex…”
Get full text

Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study by Darres, Amandine, Ulloa, Camillo, Brakemeier, Susanne, Garrouste, Cyril, Bestard, Oriol, Del Bello, Arnaud, Sberro Soussan, Rebecca, Dürr, Michael, Budde, Klemens, Legendre, Christophe, Kamar, Nassim

“…BACKGROUNDThe use of belatacept is not yet approved for maintenance in kidney transplant patients. This retrospective multicenter European study aimed to…”
Get full text

P0821OBESITY, FAT TISSUE, CELL MEMBRANE INTEGRITY PARAMETERS AND ARTERIAL STIFFNESS IN RENAL TRANSPLANT RECIPIENTS by Heleniak, Zbigniew, Illersperger, Sarah, Brakemeier, Susanne, Debska-Slizien, Alicja, Budde, Klemens, Halleck, Fabian

“…Abstract Background and Aims Arterial stiffness, altered body composition (increased body fat mass and decreased soft lean mass) and cell membrane integrity…”
Get full text

Experience with belatacept rescue therapy in kidney transplant recipients by Brakemeier, Susanne, Kannenkeril, Dennis, Dürr, Michael, Braun, Tobias, Bachmann, Friederike, Schmidt, Danilo, Wiesener, Michael, Budde, Klemens

“…In kidney transplant recipients with chronic graft dysfunction, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) can…”
Get more information

Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation by Bamoulid, Jamal, Roodenburg, Afaf, Staeck, Oliver, Wu, Kaiyin, Rudolph, Birgit, Brakemeier, Susanne, Halleck, Fabian, Lehner, Lukas, Schönemann, Constanze, Lachmann, Nils, Budde, Klemens

“…BACKGROUNDDe novo donor specific anti-HLA antibodies (dnDSA) may cause graft loss in renal transplant recipients. The capability to bind the complement may…”
Get full text